Valuation: BioRestorative Therapies, Inc.

Market Cap 5.61M 4.86M 4.56M 4.16M 7.82M 535M 7.95M 53.68M 20.96M 268M 21.06M 20.61M 894M P/E 2026 *
-0.44x
P/E 2027 * -0.54x
Enterprise Value 5.61M 4.86M 4.56M 4.16M 7.82M 535M 7.95M 53.68M 20.96M 268M 21.06M 20.61M 894M EV / Sales 2026 *
3.99x
EV / Sales 2027 * 2.43x
Free-Float
89.63%
Yield 2026 *
-
Yield 2027 * -
1 day+6.18%
1 week+14.61%
Current month+14.22%
1 month-29.15%
3 months+23.77%
6 months-12.43%
Current year-80.10%
1 week 0.2
Extreme 0.201
0.24
1 month 0.19
Extreme 0.19295
0.37
Current year 0.16
Extreme 0.1593
1.28
1 year 0.16
Extreme 0.1593
1.89
3 years 0.16
Extreme 0.1593
3.67
5 years 0.16
Extreme 0.1593
26.8
10 years 0.16
Extreme 0.1593
20,040
Manager TitleAgeSince
Chief Executive Officer 32 12/07/2026
Investor Relations Contact - -
Corporate Officer/Principal - 21/10/2025
Director TitleAgeSince
Director/Board Member 28 11/06/2026
Director/Board Member 37 11/06/2026
Director/Board Member - 12/07/2026
Date Insider Type Main position Quantity % Market Cap.
06/10/25 Free

Chief Technology Officer

23,438 0.2938%
06/10/25 Free

Chief Executive Officer

27,344 0.3427%
14/02/25 Other

Chief Technology Officer

768,979 11.1125%
Change 5-day change 1-year change 3-year change Capi.($)
+3.91%+14.61%-84.41%-91.53% 5.61M
+2.07%+13.76%+65.44%+106.53% 71.56B
-3.58%-4.69%+30.69%+59.13% 54.43B
-1.95%-5.28%-2.79%+456.86% 27.59B
-1.27%-1.57%+46.46%+6.09% 23.91B
-0.59%-2.95%-19.33%-15.39% 23.14B
-0.52%+0.75%+38.09%-20.55% 18.65B
+0.35%+12.02%+257.19%+466.50% 18.64B
-0.95%-3.52%+20.04%+613.01% 16.01B
+0.19%-6.82%+30.97%+134.24% 12.54B
Average -0.02%+4.22%+38.23%+171.49% 26.65B
Weighted average by Cap. -0.61%+3.63%+49.36%+161.53%

Financials

2026 *2027 *
Net sales 1.4M 1.22M 1.14M 1.04M 1.96M 134M 1.99M 13.44M 5.25M 67.12M 5.27M 5.16M 224M 2.31M 2M 1.88M 1.71M 3.22M 221M 3.28M 22.13M 8.64M 110M 8.68M 8.49M 369M
Net income -13.52M -11.72M -10.99M -10.02M -18.85M -1.29B -19.15M -129M -50.51M -646M -50.77M -49.67M -2.16B -15.56M -13.49M -12.64M -11.53M -21.69M -1.48B -22.04M -149M -58.11M -743M -58.41M -57.15M -2.48B
Net Debt - -
Logo BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.
Employees
14
Date Price Change Volume
14/08/26 US$0.2288 +3.91% 24,838
13/08/26 US$0.2202 +3.72% 317,405
12/08/26 US$0.2123 +1.10% 347,003
11/08/26 US$0.2100 +4.48% 312,702
10/08/26 US$0.2010 -1.47% 269,285
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.2202USD
Average target price
8.000USD
Spread / Average Target
+3,533.06%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BRTX Stock